TherapeuticsMD, Inc. (TXMD)
USD 0.98
(11.61%)
USD 0.98
(11.61%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 9.82 Million USD | -83.03% |
| 2022 | 57.9 Million USD | -72.15% |
| 2021 | 207.88 Million USD | 1.69% |
| 2020 | 204.43 Million USD | 5.1% |
| 2019 | 194.51 Million USD | 35.47% |
| 2018 | 143.58 Million USD | 56.46% |
| 2017 | 91.76 Million USD | -12.95% |
| 2016 | 105.42 Million USD | 4.56% |
| 2015 | 100.82 Million USD | 54.18% |
| 2014 | 65.39 Million USD | 100.45% |
| 2013 | 32.62 Million USD | 75.23% |
| 2012 | 18.61 Million USD | 183.46% |
| 2011 | 6.56 Million USD | 1378.53% |
| 2010 | 444.24 Thousand USD | -72.46% |
| 2009 | 1.61 Million USD | 307.81% |
| 2008 | 395.55 Thousand USD | 321.95% |
| 2007 | 93.74 Thousand USD | -69.86% |
| 2006 | 311.02 Thousand USD | -0.76% |
| 2005 | 313.4 Thousand USD | 34.52% |
| 2004 | 232.98 Thousand USD | 74.74% |
| 2003 | 133.33 Thousand USD | 21.6% |
| 2002 | 109.65 Thousand USD | -7.81% |
| 2001 | 118.93 Thousand USD | -16.72% |
| 2000 | 142.81 Thousand USD | 6.12% |
| 1999 | 134.57 Thousand USD | 6.18% |
| 1998 | 126.73 Thousand USD | 23.03% |
| 1997 | 103.01 Thousand USD | -39.26% |
| 1996 | 169.58 Thousand USD | 54.97% |
| 1995 | 109.43 Thousand USD | 0.44% |
| 1994 | 108.95 Thousand USD | 9.06% |
| 1993 | 99.9 Thousand USD | 0.0% |
| 1992 | - USD | 0.0% |
| 1991 | - USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.32 Million USD | -10.43% |
| 2024 Q2 | 1.23 Million USD | 102.27% |
| 2023 Q2 | 2.9 Million USD | -5.64% |
| 2023 Q3 | 1.72 Million USD | -40.87% |
| 2023 Q4 | 1.47 Million USD | -14.19% |
| 2023 Q1 | 3.08 Million USD | 104.87% |
| 2023 FY | 8.9 Million USD | -84.62% |
| 2022 FY | 57.9 Million USD | -72.15% |
| 2022 Q4 | -63.33 Million USD | -267.22% |
| 2022 Q3 | 37.87 Million USD | -11.22% |
| 2022 Q1 | 40.7 Million USD | -17.5% |
| 2022 Q2 | 42.66 Million USD | 4.82% |
| 2021 Q3 | 60.04 Million USD | 11.1% |
| 2021 Q2 | 54.04 Million USD | 21.57% |
| 2021 Q1 | 44.45 Million USD | -13.85% |
| 2021 Q4 | 49.33 Million USD | -17.84% |
| 2021 FY | 207.88 Million USD | 1.69% |
| 2020 FY | 204.43 Million USD | 5.1% |
| 2020 Q1 | 60.45 Million USD | 5.3% |
| 2020 Q2 | 51.33 Million USD | -15.08% |
| 2020 Q3 | 41.03 Million USD | -20.07% |
| 2020 Q4 | 51.6 Million USD | 25.75% |
| 2019 Q1 | 41.28 Million USD | -2.3% |
| 2019 Q3 | 49.34 Million USD | 6.2% |
| 2019 FY | 194.51 Million USD | 35.47% |
| 2019 Q2 | 46.46 Million USD | 12.54% |
| 2019 Q4 | 57.41 Million USD | 16.35% |
| 2018 Q4 | 42.25 Million USD | 13.8% |
| 2018 Q2 | 36.33 Million USD | 30.42% |
| 2018 Q1 | 27.85 Million USD | 10.5% |
| 2018 Q3 | 37.13 Million USD | 2.22% |
| 2018 FY | 143.58 Million USD | 56.46% |
| 2017 Q2 | 23.39 Million USD | -4.93% |
| 2017 FY | 91.76 Million USD | -12.95% |
| 2017 Q4 | 25.21 Million USD | 35.91% |
| 2017 Q3 | 18.54 Million USD | -20.73% |
| 2017 Q1 | 24.61 Million USD | -7.88% |
| 2016 Q1 | 24.79 Million USD | 13.21% |
| 2016 Q2 | 24.48 Million USD | -1.25% |
| 2016 Q3 | 29.42 Million USD | 20.18% |
| 2016 Q4 | 26.71 Million USD | -9.2% |
| 2016 FY | 105.42 Million USD | 4.56% |
| 2015 Q2 | 31.07 Million USD | 27.58% |
| 2015 FY | 100.82 Million USD | 54.18% |
| 2015 Q4 | 21.9 Million USD | -6.79% |
| 2015 Q3 | 23.49 Million USD | -24.37% |
| 2015 Q1 | 24.35 Million USD | 23.67% |
| 2014 FY | 65.39 Million USD | 100.45% |
| 2014 Q2 | 13.78 Million USD | 25.89% |
| 2014 Q3 | 20.96 Million USD | 52.08% |
| 2014 Q1 | 10.95 Million USD | 5.22% |
| 2014 Q4 | 19.69 Million USD | -6.07% |
| 2013 FY | 32.62 Million USD | 75.23% |
| 2013 Q4 | 10.4 Million USD | 17.15% |
| 2013 Q3 | 8.88 Million USD | 22.79% |
| 2013 Q2 | 7.23 Million USD | 18.6% |
| 2013 Q1 | 6.09 Million USD | -3.23% |
| 2012 Q3 | 4.64 Million USD | 4.95% |
| 2012 Q4 | 6.3 Million USD | 35.84% |
| 2012 Q2 | 4.42 Million USD | 35.89% |
| 2012 Q1 | 3.25 Million USD | -49.19% |
| 2012 FY | 18.61 Million USD | 183.46% |
| 2011 Q3 | 64.59 Thousand USD | 10.22% |
| 2011 FY | 6.56 Million USD | 1378.53% |
| 2011 Q1 | 41.73 Thousand USD | -64.92% |
| 2011 Q2 | 58.6 Thousand USD | 40.41% |
| 2011 Q4 | 6.4 Million USD | 9813.23% |
| 2010 Q2 | 83.06 Thousand USD | -76.55% |
| 2010 Q4 | 118.98 Thousand USD | 6.07% |
| 2010 Q3 | 112.17 Thousand USD | 35.05% |
| 2010 Q1 | 354.19 Thousand USD | -40.29% |
| 2010 FY | 444.24 Thousand USD | -72.46% |
| 2009 Q2 | 14.16 Thousand USD | -51.2% |
| 2009 FY | 1.61 Million USD | 307.81% |
| 2009 Q3 | 488.34 Thousand USD | 3346.57% |
| 2009 Q4 | 593.2 Thousand USD | 21.47% |
| 2009 Q1 | 29.03 Thousand USD | 242.65% |
| 2008 Q1 | 35.12 Thousand USD | 134.06% |
| 2008 FY | 395.55 Thousand USD | 321.95% |
| 2008 Q3 | 46.5 Thousand USD | -84.78% |
| 2008 Q2 | 305.45 Thousand USD | 769.69% |
| 2008 Q4 | 8473.00 USD | -81.78% |
| 2007 Q3 | 63 Thousand USD | -3.58% |
| 2007 FY | 93.74 Thousand USD | -69.86% |
| 2007 Q4 | -103.1 Thousand USD | -263.64% |
| 2007 Q2 | 65.34 Thousand USD | -3.9% |
| 2007 Q1 | 67.99 Thousand USD | -29.08% |
| 2006 Q1 | 93.23 Thousand USD | -16.97% |
| 2006 Q3 | 67.36 Thousand USD | 20.3% |
| 2006 FY | 311.02 Thousand USD | -0.76% |
| 2006 Q4 | 95.88 Thousand USD | 42.33% |
| 2006 Q2 | 56 Thousand USD | -39.94% |
| 2005 Q1 | 63.76 Thousand USD | -16.76% |
| 2005 Q2 | 70.71 Thousand USD | 10.91% |
| 2005 FY | 313.4 Thousand USD | 34.52% |
| 2005 Q3 | 66.64 Thousand USD | -5.76% |
| 2005 Q4 | 112.28 Thousand USD | 68.5% |
| 2004 Q4 | 76.59 Thousand USD | 56.18% |
| 2004 Q1 | 61.38 Thousand USD | 131.49% |
| 2004 Q2 | 45.96 Thousand USD | -25.12% |
| 2004 Q3 | 49.04 Thousand USD | 6.71% |
| 2004 FY | 232.98 Thousand USD | 74.74% |
| 2003 Q2 | 32.87 Thousand USD | -23.38% |
| 2003 FY | 133.33 Thousand USD | 21.6% |
| 2003 Q4 | 26.51 Thousand USD | -14.59% |
| 2003 Q3 | 31.04 Thousand USD | -5.55% |
| 2003 Q1 | 42.89 Thousand USD | 55.75% |
| 2002 Q4 | 27.54 Thousand USD | 13.59% |
| 2002 Q1 | 29.51 Thousand USD | 104.37% |
| 2002 Q2 | 28.34 Thousand USD | -3.97% |
| 2002 FY | 109.65 Thousand USD | -7.81% |
| 2002 Q3 | 24.24 Thousand USD | -14.44% |
| 2001 Q2 | 33.54 Thousand USD | -7.62% |
| 2001 Q1 | 36.31 Thousand USD | -2.3% |
| 2001 FY | 118.93 Thousand USD | -16.72% |
| 2001 Q4 | 14.44 Thousand USD | -58.29% |
| 2001 Q3 | 34.62 Thousand USD | 3.22% |
| 2000 Q3 | 31.36 Thousand USD | -14.67% |
| 2000 Q2 | 36.75 Thousand USD | -37.68% |
| 2000 Q1 | 58.98 Thousand USD | 47.62% |
| 2000 FY | 142.81 Thousand USD | 6.12% |
| 2000 Q4 | 37.17 Thousand USD | 18.51% |
| 1999 Q1 | 47.67 Thousand USD | 0.0% |
| 1999 Q3 | 30.42 Thousand USD | 4.71% |
| 1999 Q2 | 29.05 Thousand USD | -39.06% |
| 1999 FY | 134.57 Thousand USD | 6.18% |
| 1999 Q4 | 39.95 Thousand USD | 31.34% |
| 1998 FY | 126.73 Thousand USD | 23.03% |
| 1997 FY | 103.01 Thousand USD | -39.26% |
| 1996 FY | 169.58 Thousand USD | 54.97% |
| 1995 FY | 109.43 Thousand USD | 0.44% |
| 1994 FY | 108.95 Thousand USD | 9.06% |
| 1993 FY | 99.9 Thousand USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| 1991 FY | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -19.049% |
| Alpha Teknova, Inc. | 45.85 Million USD | 78.576% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 94.987% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 78.096% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 93.829% |
| Cosmos Health Inc. | 26.18 Million USD | 62.472% |
| Journey Medical Corporation | 54.59 Million USD | 82.004% |
| Embecta Corp. | 528.4 Million USD | 98.141% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 96.386% |
| Dynavax Technologies Corporation | 219.14 Million USD | 95.517% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 98.335% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 96.99% |
| PainReform Ltd. | 9.58 Million USD | -2.515% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | 25.14% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | 25.14% |
| SCYNEXIS, Inc. | 51.84 Million USD | 81.05% |
| Safety Shot Inc | 12.1 Million USD | 18.867% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -220.117% |
| Procaps Group, S.A. | 199.47 Million USD | 95.075% |
| Theratechnologies Inc. | 72.75 Million USD | 86.496% |
| Harrow Health, Inc. | 89.97 Million USD | 89.08% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -4.012% |
| Biofrontera Inc. | 39.95 Million USD | 75.412% |
| DURECT Corporation | 43.71 Million USD | 77.525% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 98.143% |
| Cronos Group Inc. | 96.7 Million USD | 89.841% |
| OptiNose, Inc. | 85.1 Million USD | 88.455% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 95.767% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 74.906% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 202.761% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 96.872% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -0.968% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 77.173% |
| Radius Health, Inc. | 265.92 Million USD | 96.305% |
| Universe Pharmaceuticals INC | 13.84 Million USD | 29.02% |
| ProPhase Labs, Inc. | 37.85 Million USD | 74.044% |
| Phibro Animal Health Corporation | 260.29 Million USD | 96.225% |
| Procaps Group S.A. | 187.24 Million USD | 94.753% |
| Alvotech | 285.43 Million USD | 96.558% |
| Viatris Inc. | 5.96 Billion USD | 99.835% |
| Rockwell Medical, Inc. | 15.37 Million USD | 36.093% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 83.581% |
| SIGA Technologies, Inc. | 22.04 Million USD | 55.428% |
| Tilray Brands, Inc. | 251.35 Million USD | 96.091% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 79.965% |
| Shineco, Inc. | 17.94 Million USD | 45.259% |
| PetIQ, Inc. | 192.72 Million USD | 94.902% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -146.17% |
| Incannex Healthcare Limited | 30.05 Million USD | 67.308% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 99.385% |
| Alimera Sciences, Inc. | 62.64 Million USD | 84.315% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -1188.538% |
| Assertio Holdings, Inc. | 368.58 Million USD | 97.334% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -66.934% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | 44.83% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | 53.588% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 53.308% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 94.044% |
| Hempacco Co., Inc. | 7.59 Million USD | -29.337% |
| Talphera, Inc. | 11.99 Million USD | 18.084% |
| Alvotech | 285.43 Million USD | 96.558% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 93.018% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 97.151% |
| Currenc Group, Inc. | 24 Million USD | 59.066% |
| Kamada Ltd. | 45.42 Million USD | 78.371% |
| Indivior PLC | 911 Million USD | 98.922% |
| Evoke Pharma, Inc. | 12.4 Million USD | 20.828% |
| Flora Growth Corp. | 10.57 Million USD | 7.127% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 53.308% |
| Evolus, Inc. | 189.75 Million USD | 94.822% |
| HUTCHMED (China) Limited | 436.23 Million USD | 97.748% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 93.626% |
| Akanda Corp. | 3.48 Million USD | -182.043% |